INTRODUCTION: Bone mineral density (BMD) and fracture rates in children with
osteogenesis imperfecta (OI) have been shown to improve with bisphosphonate therapy …

Recent non-placebo-controlled studies of the bisphosphonate pamidronate have shown it to
be effective in reducing fractures and improving bone density in infants and children with …

Osteoporosis is increasingly being seen in young people. The primitive forms are relatively
rare, but the secondary forms—particularly in long-term corticosteroid therapy—are a …

Bisphosphonates are synthetic analogues of pyrophosphate that inhibit bone resorption by
their action on osteoclasts. In recent years, bisphosphonates have been used in children for …

Background: Pamidronate therapy is increasingly used in children for the treatment of low
bone mineral density and increased bone fragility resulting from a spectrum of conditions …

THE JOURNAL OF PEDIATRICS EDITORIALS VOLUME 134, NUMBER 3 it macrophage
activity, which may contribute to their efficacy in treating the hypercalcemia associated with …

The last 2 years have seen additions proposed to the very limited armamentarium of
treatments for osteogenesis imperfecta. These include the use of bisphosphonates to …

In this double-blind randomised placebo-controlled trial it was investigated during a two-
year follow-up whether oral bisphosphonates (Olpadronate 10 mg/m 2/day) influence quality …

Mucolipidosis type III (ML III; McKusick 252600) is a rare lysosomal storage disease in which
skeletal involvement is prominent, in particular the destruction of vertebral bodies and the …

Osteoporosis is characterized by loss of both bone mass and microarchitectural integrity,
resulting in an increased risk of fractures with associated morbidity and mortality. Awareness …